High expression levels of X-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3737-3744

  Tamm, Ingo ^a,d   Richter, Stephan ^a   Oltersdorf, Doreen ^a   Creutzig, Ursula ^b   Harbott, Jochen ^c   Scholz, Frank ^d   Karawajew, Leonid ^a   Ludwig, Wolf Dieter ^a   Wuchter, Christian ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 1; FAS ANTIGEN; PROCASPASE 3; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL MATURATION; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; INFANT; LEUKEMIA CELL; MALE; NEWBORN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; WESTERN BLOTTING;

ADOLESCENT; ANTIGENS, CD95; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CASPASES; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK; TIME FACTORS; TREATMENT OUTCOME; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 2542549018     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0642     Document Type: Article

References (38)

1. Tamm I, Schriever F, Dorken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol 2001;2:33-42.
2. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
3. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science (Wash DC) 1995;267:1456-62.
4. Del Poeta G, Venditti A, Del Principe MI, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003;101:2125-31.
5. Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001;97:2784-90.
6. Oliver L, Vavasseur F, Mahe B, et al. Assessment of caspase activity as a possible prognostic factor in acute myeloid leukaemia. Br J Haematol 2002;118:43-7.
7. Svingen PA, Karp JE, Krajewski S, et al. Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood 2000;96:3922-31.
8. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803.
9. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000;111:196-203.
10. Lewis NR, Pallis M, Russell NH. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia. Exp Hematol 2000;28:535-42.
11. Wuchter C, Karawajew L, Ruppert V, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia (Baltimore) 1999;13: 1943-53.
12. Estrov Z, Thall PF, Talpaz M, et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 1998;92:3090-7.
13. Iijima N, Miyamura K, Itou T, Tanimoto M, Sobue R, Saito H. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. Blood 1997;90:4901-9.
14. Lauria F, Raspadori D, Rondelli D, et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia (Baltimore) 1997;11:2075-8.
15. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia (Baltimore) 1995;9:1191-8.
16. Kem W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003;101:64-70.
17. O'Brien TA, Russell SJ, Vowels MR, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. Blood 2002;100:2708-16.
18. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001;19:2705-13.
19. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, Buchner T. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999;17:3569-76.
20. Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer 1999;35:173-85.
21. Russell NH. Biology of acute leukaemia. Lancet 1997;349:118-22.
22. Wuchter C, Richter S, Oltersdorf D, et al. Differences in the expression pattern of apoptosis-related molecules between childhood and adult de novo acute myeloid leukaemia. Hematologica 2004;89: 363-4.
23. Schimmer AD, Hedley DW, Penn LZ, Minden MD. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood 2001;98:3541-53.
24. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620-5.
25. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
26. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia (Baltimore) 1995;9:1783-6.
27. Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia (Baltimore) 2001;15:348-54.
28. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20.
29. Mitelman F. ISCN 1995, guidelines for cancer cytogenetics. Supplement to: an international system for human cytogenetic nomenclature. Basel: Karger, 1995.
30. Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001;112:118-26.
31. Lin H, Chen C, Li X, Chen BD. Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differentiation and up-regulation of X-linked inhibitor of apoptosis protein. Exp Cell Res 2002;272:192-8.
32. Miranda MB, Dyer KF, Grandis JR, Johnson DE. Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells. Leukemia (Baltimore) 2003;17: 390-400.
33. Carter BZ, Milella M, Tsao T, McQueen T, et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 17:2081-9.
34. Schoch C, Haferlach T. Cytogenetics in acute myeloid leukemia. Curr Oncol Rep 2002;4:390-7.
35. Zwaan CM, Kaspers GJ, Pieters R, et al. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 2002;100:3352-60.
36. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96: 1921-5.
37. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998;351:882-3.
38. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res., 1998;58: 1808-12.